Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jinxin Fertility Group Limited
錦欣生殖醫療集團有限公司*
(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 1951)

VOLUNTARY ANNOUNCEMENT KEY OPERATING DATA FOR THE FOUR MONTHS ENDED APRIL 30, 2026

This is a voluntary announcement made by Jinxin Fertility Group Limited (the "**Company**") to keep the shareholders of the Company and potential investors informed of the latest business developments of the Company and its subsidiaries (the "**Group**").

The board of directors (the "**Board**") of the Company is pleased to announce that, through continuous efforts in implementing operational optimization initiatives, the Group maintained strong growth momentum. The number of new patient visits for infertility ("**NPVs**") reached 16,525 for the four months ended April 30, 2026, representing an increase of 7.5% compared to the same period in 2025. The number of oocyte pick up cycles ("**OPU Cycles**") for the four months ended April 30, 2026 was 9,010, representing a period-on-period increase of 5.2%.

In particular:

- **Greater Bay Area:** For the four months ended April 30, 2026, the number of NPVs increased by 17.7% as compared with the same period last year. The new campus of the Group's Shenzhen Zhongshan Obstetrics and Gynecology Hospital commenced trial operations in February 2026, completed all license transfers by the end of March 2026, and launched a comprehensive upgrade of its VIP business in the third quarter of 2026, introducing in vitro fertilization ("**IVF**") obstetrics services to achieve an integrated, end-to-end pregnancy and childbirth care pathway. The Group's clinic in Hong Kong is undergoing renovation and upgrades, and the Group will subsequently implement Hong Kong-Shenzhen collaboration to establish an international medical center, further unlocking the potential and capacity of the Greater Bay Area.

- **Overseas:** For the four months ended April 30, 2026, the number of OPU Cycles increased by 37.3% as compared with the same period last year. Benefiting from the formal implementation of California's Senate Bill 729 since 2026 and the successful physician recruitment over the past three years, the number of OPU Cycles set a new record high for three consecutive months starting from February to April 2026.

- **Chengdu region:** Both the number of NPVs and OPU Cycles recorded single-digit declines. This was primarily attributable to the Group's proactive response, beginning in the first quarter of 2026, to the national "15th Five-Year Plan" initiative promoting eugenics and fertility-friendly policies, under which genetic disease screening was introduced during the preconception period. As screening results generally take longer to process than routine physical examination results, patients experienced delays in entering treatment cycles. For the four months ended April 30, 2026, the number of third-generation IVF cycles increased by 16.8% period-on-period.

- **Kunming and Wuhan region:** The number of OPU Cycles for the four months ended April 30, 2026 increased by 15.5% as compared to the same period in 2025, maintaining steady growth.

For the four months ended April 30, 2026, the Group's business and operations remain as usual. In particular, based on the management's operational data, the medical pricing has been stable and the Group continues to record steady revenue growth.

The table below sets forth the number of NPVs and the number of OPU Cycles for the four months ended April 30, 2026, with comparative figures for the corresponding periods in 2025:

Region	**Number of NPVs[(1)]**			**Number of OPU Cycles**		
	For the four months ended April 30,		**Period-on-period changes**	**For the four months ended April 30,**		**Period-on-period changes**
	2025	**2026**		**2025**	**2026**	
Chengdu	7,159	7,083	-1.1%	4,393	4,095	-6.8%
Greater Bay Area	2,949	3,470	17.7%	1,580	1,621	2.6%
Kunming and Wuhan	2,889	2,930	1.4%	1,229	1,420	15.5%
Overseas[(2)]	2,371	3,042	28.3%	1,365	1,874	37.3%
Total	**15,368**	**16,525**	**7.5%**	**8,567**	**9,010**	**5.2%**

Notes:

(1) NPVs: Patients (including couples) who visit the Group's hospitals' department of reproductive medicine or assisted reproductive centers for the first time, have not previously established any medical records related to infertility or assisted reproduction at the Group's facilities, and have no prior reproductive medicine consultation records. This refers to the first registration for fertility assessment, infertility screening, or planned assisted reproductive treatment (intrauterine insemination or in-vitro fertilization).

(2) The overseas business in 2025 included the Jinrui Medical Center in Laos and the Company has terminated its operations in Laos in 2025. Excluding the Group's business in Laos, the number of OPU cycles of Huntington Reproductive Center Medical Group in the US increased by 39.4% period-on-period.

Going forward, the Group will continue to strengthen the iterative upgrading of its core reproductive medical technologies, continuously optimize the diagnosis and treatment service processes and enhance service quality and patient experience. By delivering high-quality medical services, the Group aims to solidify its operational foundation, promote high-quality business growth, and create long-term, stable value returns for shareholders.

The Company wishes to provide the shareholders and potential investors of the Company with a business update and the information contained herein is based on a preliminary assessment of the Group and the information currently available to the Company and is not based on any figure or information which has been audited or reviewed by the auditor of the Company. The above figures contained in this announcement are for illustrative purposes only, and do not constitute forward-looking statements or profit numbers.

Shareholders and potential investors of the Company are reminded to rationally deal with any information not officially released by the Company, and shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By order of the Board
Jinxin Fertility Group Limited
Dong Yang
Chief Executive Officer,
Acting Chief Financial Officer
and Executive Director

Hong Kong, May 6, 2026

As at the date of this announcement, the Board comprises Mr. Dong Yang, Dr. Lyu Rong and Dr. Geng Lihong, as executive directors; Mr. Zhong Yong, as chairman and non-executive director, and Ms. Hu Zhe, Ms. Yan Xiaoqing and Mr. Chen Shuyun, as non-executive directors; and Dr. Chong Yat Keung, Dr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive directors.

* *For identification purposes only*